DYNAMIC trial data spark Twitter talk about ‘future of patient risk stratification’

The potential for ctDNA-guided management to reduce adjuvant chemotherapy by half without compromising recurrence-free survival sparked interest on social media after a presentation at the ASCO Annual Meeting.Fresh off a presentation by Jeanne Tie, MD, MBChB, FRACP, on the DYNAMIC trial, Healio and Creation Healthcare, a digital insights company, analyzed health care provider sentiments on the results.Paolo Tarantino, MD (@PTarantinoMD). June 4, 2022. The MRD revolution has started. In this trial (n=455), stage II CRC pts were randomized to standard management or ctDNA-guided (no adj chemo ifRead More

Categories: News

Related Articles

2019 Telehealth Bill

In 2019, Florida passed the Telehealth Bill which establishes standards of practice for telehealth services, including patient evaluations, record-keeping, and controlled substances prescribing. The bill…

Justin Bouck July 9, 2019

2018 FGS Annual Meeting Registration Is Now Open!

Registration for the 2018 FGS Annual Meeting is now open! We will be returning to the Hyatt Regency Grand Cypress this September 14-16, 2018. Short…

Justin Bouck May 22, 2018

Modified FOLFIRINOX ‘recommended adjuvant regimen’ for patients with pancreatic cancer

Adjuvant chemotherapy with modified FOLFIRINOX resulted in significantly longer survival vs. gemcitabine among patients with previously resected pancreatic ductal adenocarcinoma, according to 5-year data from…

September 1, 2022

Older age not linked to increased risk for Crohn’s recurrence after surgical resection

SAN DIEGO — The risk for postoperative recurrence of Crohn’s disease after ileocolic resection did not increase among older patients compared with a younger cohort,…

Let’s Talk About Physician Burnout

Physician Burnout has become a serious topic of discussion in the healthcare field lately. With such a large array of factors affecting the well-being…

Justin Bouck June 5, 2018